question stringlengths 13 163 | answer stringlengths 1 525 |
|---|---|
What is the name of the investigational medicinal product? | TJ301 (solution for injection), also referred to as FE 999301 and Olamkicept |
What is the indication for the clinical trial? | Active Ulcerative Colitis |
Who is the Coordinating Investigator? | Prof. Dr. Minhu Chen |
What is the purpose of this trial? | This trial will be performed in compliance with GCP. |
Who owns the information in this document? | Leading Biopharm Limited |
What is required to disclose information from this document? | Prior written consent of an authorised officer of Leading Biopharm Limited |
What is the date of this clinical study protocol? | 16 May 2017 |
What are the ethical principles that this study will be conducted with? | The Declaration of Helsinki and ICH E6 Good Clinical Practice: Consolidated Guideline |
Who are the representatives of the sponsor? | Yin Liu, MD (Clinical Medical Director) and Taylor B. Guo, PhD (Chief Science Officer) |
What is the date of this clinical study protocol? | 16 May 2017 |
What are the ethical principles that this study will be conducted with? | The Declaration of Helsinki |
What is the name of the company where Jiali Liu and Weiyan Dai work? | Mosim Co., Ltd |
What is the date of this document? | 16 May 2017 |
What does the Investigator agree to conduct the study in accordance with? | the requirements of this protocol and also protect the rights, safety, privacy, and well-being of study patients |
What principles and guidelines does the Investigator agree to follow? | The Declaration of Helsinki, International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated Guideline, and all applicable laws and regulations |
What is the date of this document? | 16 May 2017 |
What version of the protocol is this? | Ver.1.1 |
What is the document date of issue for version V1.0? | 22 Feb 2017 |
What is the title of the clinical trial? | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients with Active Ulcerative Colitis |
Who is the Coordinating Investigator of the trial? | Prof. Dr. Minhu Chen |
Where will the trial be conducted? | Multicenter, international across Mainland China, Taiwan, Republic of Korea and Australia |
What are the primary objectives of the investigation? | To investigate the pharmacodynamics (PD) of TJ301 in patients with active ulcerative colitis and to investigate immunogenicity of TJ301 in patients with active ulcerative colitis. |
What is being investigated in patients with active ulcerative colitis? | The pharmacodynamics (PD) of TJ301 and its immunogenicity. |
What is TJ301 being investigated for? | Active ulcerative colitis. |
What is the purpose of the TJ301 Protocol? | To explore the relationship between PK and PD of TJ301 in patients with active ulcerative colitis. |
What are the primary endpoints of the clinical trial? | Clinical and endoscopic remission at Week 12, and adverse events, vital signs, 12-lead Electrocardiography (ECG), and clinical safety laboratory abnormalities. |
What is mucosal healing defined as in the clinical trial? | Mayo endoscopic subscore = 0 or 1 at Week 12. |
What are the exploratory endpoints in the study? | Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers (erythrocyte sedimentation rate [ESR], C-reactive protein (CRP), IL-6, IL-6/sIL-6R complex, neutrophil and platelet count, faecal calprotectin) |
What is FDA-defined remission at Week 12? | Stool frequency subscore=0, Rectal bleeding subscore=0, and Endoscopy subscore =0 or 1 |
What PK subgroup parameters are measured? | AUCinf, AUCt, %AUCext, Cmax, tmax, CL, Vz, λz, t½, and MRT (if applicable) |
What type of study is this? | A multicenter, randomized, double-blind, placebo-controlled phase II study. |
How many patients will be assigned to the study? | 90 patients |
How often will TJ301 or placebo be administered? | Biweekly (Q2W) |
What is the duration for which corticosteroids should be stable prior to Randomization? | at least 2 weeks |
What is the minimum dose of 5-ASA required per day for at least 3 months prior to Randomization? | 2 g |
What is the minimum duration for which azathioprine (AZA) or mercaptopurine (6-MP) should be taken prior to Randomization? | 6 months |
What is the duration of the Screening Period? | 28 days prior to Visit 2 |
How many visits are scheduled during the 12-week Treatment Period? | 7 visits |
When is the Safety Follow-up Visit scheduled? | 35 days after the last dose of IMP (Day 105) |
How many patients will be enrolled in the study? | 90 patients with active UC |
What is the purpose of the Safety Follow-up Visit for patients not completing the trial? | Scheduled 35 days after the last dose of IMP |
How many blood samples will be collected after the start of the 6th administration? | 11 samples |
What is the age range for patients in this clinical trial? | 18-70 (inclusive) years of age. |
What is the requirement for female patients in this clinical trial? | A female subject has been sterilized or has been menopausal, or the subject has no pregnancy plan during the trial and voluntarily adopts effective contraceptive measures. |
What is the requirement for patients to participate in this clinical trial? | The patient is able and willing to comply with the requirements of this trial protocol. |
What is the requirement for a patient to participate in this trial? | The patient must be able and willing to comply with the requirements of this trial protocol. |
What is the requirement for a patient to understand and fill out the Patient Diary? | The subject should be able to read and write. |
What is the condition for a patient to be eligible for inclusion in this study? | Voluntarily signed Informed Consent obtained before any trial-related procedures are performed. |
What are the conditions that lead to exclusion from the clinical trial? | Moderate to severe anaemia, thrombocytopenia, autoimmune disease, Clostridium difficile positive, known clinically relevant chronic liver disease, serious underlying disease, drug addiction, and regular use of more than 40 grams of alcohol every day. |
What is the threshold for serum creatinine to be excluded from the trial? | Serum creatinine >2 mg/dL. |
What is the threshold for serum transaminases and alkaline phosphatase in the absence of primary sclerosing cholangitis? | Serum transaminases >2.5 x ULN, alkaline phosphatase >2.5 x ULN. |
Is there a history of drug addiction within the last 1 year or current drug addiction? | Yes |
Is there regular use of more than 40 grams of alcohol every day? | Yes |
Is there a history of active tuberculosis (TB) or latent TB infection? | Yes |
What is the time frame for receiving live (attenuated) vaccines before Randomisation? | 30 days prior to Randomisation. |
What is the condition for treatment with medium-to-high-dose intravenous corticosteroids before Randomisation? | within 8 weeks prior to Randomisation or oral corticosteroids of more than 20 mg prednisone within 30 days prior to Randomisation. |
How long should the infusion time of the IMP be? | 2 hours. |
What is the recommended storage temperature for both placebo and TJ301? | -20±5 °C |
How long should the infusion time be? | 2 hours |
What is the expected sample size for the study to achieve a power of 83%? | N=72 (n=24 per treatment/placebo arm) patients |
What is the required power to reach a statistically significant result in the clinical trial? | 70% |
What is the dropout rate considered in the clinical trial? | 20% |
How many patients will be enrolled competitively in the clinical trial? | 90 |
What statistical model will be used to analyze continuous endpoints? | Repeated measures Analysis of Covariance (ANCOVA) model |
How will patients be split for comparison in endpoints? | Based on the baseline level of IL-6/sIL-6R complexes |
How will PK parameters be derived? | Using noncompartmental method |
What is the date of the document? | 16 May 2017 |
What is the protocol number? | CTJ301UC201 |
What is the document classified as? | CONFIDENTIAL |
What is the purpose of the trial? | Scientific Justification for Conducting the Trial |
What are the main objectives of the trial? | Objectives |
What is the overall design of the trial? | Overall Trial Design |
What are the main sections of the trial design? | 3.1.1 Trial Design Diagrams, 3.1.2 Overall Design, 3.1.3 Trial Schedule |
What is the purpose of the Safety Review Committee? | Not specified in the given text |
What are the key components of the trial design? | Trial Design, Selection of Endpoints, Blinding, Selection of Doses in the Trial |
What section of the text deals with the selection and timing of dose for each patient? | 3.4.5 |
What section of the text deals with the follow-up procedures? | 3.4.7 |
What section of the text deals with the method of assigning patients to treatment groups? | 4.2 |
What are the prior and concomitant therapies? | Not specified in the given text |
What therapy is prohibited? | Not specified in the given text |
What are the other restrictions? | Not specified in the given text |
What is the date of this document? | 16 May 2017 |
What is the protocol number? | CTJ301UC201 |
How many treatments are described in this protocol? | 5 |
What is the purpose of the run-in period? | Stabilization Period |
What is the duration of the screening period? | Days -28 to -1 prior to Visit 2 |
How long is the 12-week treatment period? | Visits 3 to 8 |
What is the purpose of the 12-week treatment period? | Visits 3 to 8 |
What type of visits are PK visits? | PK Visits |
What is the purpose of the safety follow-up visit? | Visit 9 |
What assessments are mentioned in the text? | Electrocardiogram, Trial-specific Blood and Faeces Sampling, and Other Assessments |
What is included in the Other Assessments? | Demography, Medical and Surgical History, Ulcerative Colitis History and Previous Therapy for Ulcerative Colitis, Concomitant Medication Review, and Urine Screening for Drugs of Abuse |
Where are drug concentration measurements handled? | Drug Concentration Measurements are handled in section 7.4 |
What is the definition of Adverse Event? | 8.1 Adverse Event Definition |
Where is the section on Collection and Recording of Adverse Events located? | 8.2 Collection and Recording of Adverse Events |
What is the section number for Serious Adverse Events? | 8.5 Serious Adverse Events |
What is the date of this document? | 16 May 2017 |
What does the protocol number CTJ301UC201 refer to? | TJ301 Protocol |
What is the section about? | Statistical Methods |
What is the Intention-to-Treat Analysis Set? | 9.4.1 Intention-to-Treat Analysis Set |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4